Clinical trials: Hypereosinophilic Syndrome
Asthma
Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma
The aim of the project is to study the persistence of inflammation after addition of an interleukin-5 (IL-5) blocker in severe eosinophilic asthma as a study of untreated pathways in these patients.
- Trial name
- MAPLE (NCT03610685)
- Testing
- Prednisolone
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- NHS Greater Glasgow and Clyde
Eosinophilic Asthma
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients…
- Trial name
- NCT01270464
- Testing
- Reslizumab
- Where
- 89 sites in United States, Argentina and 11 more
- Volunteers
- 315 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Eosinophilia, Hypereosinophilic Syndrome
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
Eosinophils are a type of white blood cell. Elevated eosinophil levels can damage the heart, nerves, and other organs, in the syndrome known as hypereosinophilic syndrome (HES).
- Trial name
- NCT00091871
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Eosinophilic Asthma
Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
The purpose of this study is to identify differentially expressed gene transcripts after initiation of mepolizumab in individuals with severe eosinophilic asthma (SEA).
- Trial name
- NCT05002621
- Testing
- Observational
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Bronchial Asthma, Eosinophilic Asthma
XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma
A multicenter, double-blind, randomized, pilot study in parallel groups to assess the efficacy and safety of XC8 at a dose of 100 mg versus placebo over a 12-week treatment period in non-smoking patients with a confirmed…
- Trial name
- NCT04674137
- Testing
- XC8 100 mg
- Where
- 18 sites in Russia
- Volunteers
- 70 people
- Sponsor
- Chemlmmune Therapeutics LLC
Stroke Patients Presenting Within 24 Hrs of Onset of Symptoms
Influence of Hydroxyehtyl Starch (HES) on Hemorehology, Coagulation and Elimination Kinetics
The use of HES has been found clinically to improve patients with stroke if administered within a window period by means of hemodilution to improve rehology.
- Trial name
- NCT00255957
- Testing
- HES administration, Hydroxy Ethyl Starch administration to stroke patients
- Volunteers
- 20 people
- Sponsor
- Nizam's Institute of Medical Sciences University, India
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions: Relapsed/refractory Ph+ Acute…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis
- Trial name
- NCT00109707
- Testing
- Nilotinib
- Where
- 101 sites in United States, Australia and 20 more
- Volunteers
- 507 people
- Sponsor
- Novartis Pharmaceuticals
Dactinomycin Adverse Reaction, Bone and Joint Infection
Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections
the aim of this study is to investigate the relationship between exposure to daptomycin and the occurrence of muscle toxicity or eosinophilic pneumonia in patients treated with daptomycin for bone and joint infection
- Trial name
- PKTOXDAP (NCT04933344)
- Testing
- patients having had BJI or PJI treated with daptomycin
- Where
- France
- Volunteers
- 1,130 people
- Sponsor
- Hospices Civils de Lyon
Asthma, Eosinophilic Asthma
Intense Airway Eosinophilia in Asthma
In asthma, the type and importance of the inflammatory response in the airways has allows identification of different phenotypes.
- Trial name
- NCT03696914
- Where
- Canada
- Volunteers
- 918 people
- Sponsor
- Laval University
Severe Eosinophilic Asthma
Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma
This study investigates the effect of removing eosinophils from peripheral blood (using treatment with Benralizumab, which is approved for the treatment of severe eosoniphilic asthma) on circulating dendritic cells in patients…
- Trial name
- NCT03652376
- Testing
- Benralizumab
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Rostock
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Asthma; Eosinophilic
Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients
Real-life, observational, retrospective, multicenter study to evaluate the effects of anti-IL5 biological treatments on blood total IgE Levels in atopic patients with severe eosinophilic asthma.
- Trial name
- BIONIGE (NCT04181190)
- Testing
- Total IgE, Blood cell counts, Asthma control assessment
- Where
- 8 sites in Italy
- Volunteers
- 130 people
- Sponsor
- Università degli Studi di Ferrara
EGPA - Eosinophilic Granulomatosis With Polyangiitis, HES - Hypereosinophilic Syndrome
The Use of Machine Learning Techniques for the Differential Diagnosis Between Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome
The purpose of this study is to collect clinical, laboratory, and instrumental data from patients with eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome, which will then be analyzed using artificial…
- Trial name
- NCT07275190
- Testing
- Blood draw for the laboratory assessment
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Asthma
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
This is a multi-centre, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma on markers of asthma control.
- Trial name
- NCT02281318
- Testing
- Mepolizumab, SOC
- Where
- 144 sites in United States, Argentina and 17 more
- Volunteers
- 556 people
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis
- Trial name
- NCT00255346
- Testing
- Dasatinib (BMS-354825)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
Severe Eosinophilic Asthma
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
The aim is to study the effect of OC000459 on eosinophilic airway inflammation and asthma control in subjects with severe, refractory eosinophilic asthma.
- Trial name
- NCT02560610
- Testing
- OC000459
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Eosinophilic Asthma
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed by…
- Trial name
- NCT01290887
- Testing
- Reslizumab
- Where
- 219 sites in United States, Argentina and 29 more
- Volunteers
- 1,052 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Primary Myelofibrosis, Polycythemia Vera
Myeloproliferative Neoplasms (MPNs) Patient Registry
The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.
- Conditions
- Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Mastocytosis
- Trial name
- NCT02760238
- Testing
- Observational
- Where
- Canada
- Volunteers
- 5,000 people
- Sponsor
- University Health Network, Toronto
Hypereosinophilic Syndrome
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Mepolizumab is a humanized monoclonal antibody. In conditions where eosinophilia is considered to play an important part in the pathology, including eosinophilic asthma, HES, and eosinophilic granulomatosis with polyangiitis, a…
- Trial name
- NCT02836496
- Testing
- Mepolizumab 300 mg, Active OCS capsules (5 mg prednisolone or prednisone)
- Where
- 43 sites in United States, Argentina and 11 more
- Volunteers
- 108 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
This clinical trial aims to investigate patients with poorly controlled, moderate to severe eosinophilic asthma. The main questions it seeks to answer are 1.
- Trial name
- NCT05985694
- Testing
- AD17002
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Advagene Biopharma Co. Ltd.